[go: up one dir, main page]

CA2676583C - Composition renfermant de la levure de riz rouge et un acide gras omega-3 polyinsature - Google Patents

Composition renfermant de la levure de riz rouge et un acide gras omega-3 polyinsature Download PDF

Info

Publication number
CA2676583C
CA2676583C CA2676583A CA2676583A CA2676583C CA 2676583 C CA2676583 C CA 2676583C CA 2676583 A CA2676583 A CA 2676583A CA 2676583 A CA2676583 A CA 2676583A CA 2676583 C CA2676583 C CA 2676583C
Authority
CA
Canada
Prior art keywords
composition
red yeast
yeast rice
omega
epa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2676583A
Other languages
English (en)
Other versions
CA2676583A1 (fr
Inventor
Joar Opheim
Douglas Mackay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordic Naturals Inc
Original Assignee
Nordic Naturals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Naturals Inc filed Critical Nordic Naturals Inc
Priority to CA2676583A priority Critical patent/CA2676583C/fr
Publication of CA2676583A1 publication Critical patent/CA2676583A1/fr
Application granted granted Critical
Publication of CA2676583C publication Critical patent/CA2676583C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un médicament renferme une dispersion de levure de riz rouge dans un acide gras Omega-3. Le médicament est fourni en capsules de sorte quune dose quotidienne est distribuée dans un nombre entier de capsules. Un dispersant est utilisé, préférablement de la lysine et du bambou. Le rapport dextrait de levure de riz rouge aux EPA+DHA est de lordre de 1,4 à 2,8. Le médicament réduit le taux de cholestérol, de triglycérides et réduit les incidents cardiaques graves.
CA2676583A 2009-08-25 2009-08-25 Composition renfermant de la levure de riz rouge et un acide gras omega-3 polyinsature Active CA2676583C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2676583A CA2676583C (fr) 2009-08-25 2009-08-25 Composition renfermant de la levure de riz rouge et un acide gras omega-3 polyinsature

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2676583A CA2676583C (fr) 2009-08-25 2009-08-25 Composition renfermant de la levure de riz rouge et un acide gras omega-3 polyinsature

Publications (2)

Publication Number Publication Date
CA2676583A1 CA2676583A1 (fr) 2011-02-25
CA2676583C true CA2676583C (fr) 2017-03-07

Family

ID=43618903

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2676583A Active CA2676583C (fr) 2009-08-25 2009-08-25 Composition renfermant de la levure de riz rouge et un acide gras omega-3 polyinsature

Country Status (1)

Country Link
CA (1) CA2676583C (fr)

Also Published As

Publication number Publication date
CA2676583A1 (fr) 2011-02-25

Similar Documents

Publication Publication Date Title
US20080299187A1 (en) Substances for Reducing Occurence of Major Cardiac Events in Humans
US11406602B2 (en) Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US11684600B2 (en) Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
CA2640414C (fr) Combinaisons d'extraits botaniques pour favoriser la sante cardio-vasculaire
RU2179440C2 (ru) Композиция и способы подавления роста опухолевых клеток и опухоли с ее использованием
KR20080033410A (ko) 페노피브레이트 및 스타틴을 포함하는 신규한 제제 및 관련치료방법
AU2012211854A1 (en) Prophylactic or therapeutic drug for peripheral neuropathy caused by anticancer agent
US20120171285A1 (en) Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract
US20210106541A1 (en) Natural combination products and methods for regulation of total blood cholesterol
Choe et al. In vivo anti-obesity effects of Monascus pigment threonine derivative with enhanced hydrophilicity
US20120172425A1 (en) Red yeast rice extract high in monacolin k content
CA2676583C (fr) Composition renfermant de la levure de riz rouge et un acide gras omega-3 polyinsature
KR20140144433A (ko) 파리유충 에탄올 추출물을 유효성분으로 포함하는 고지혈증 예방 또는 치료용 약제학적 조성물
WO2013138409A1 (fr) Extrait de riz à levure rouge à teneur élevée en monacoline k
WO2013138407A1 (fr) Substances permettant d'atténuer la survenue d'événements cardiaques majeurs comprenant de l'epa ou des dérivés de ceux-ci, facultativement, l'acide docosahexanoïque (dha) ou des dérivés de celui-ci et la monacoline k
BG2003U1 (bg) Средство за профилактика и регулиране на нивото на общия холестерол
RU2655803C2 (ru) Фармацевтическая композиция для профилактики и лечения атеросклероза
RU2211043C2 (ru) Композиция для приготовления лекарственных форм и обогащения продуктов питания, способствующая коррекции нарушений липидного обмена, профилактики и лечения атеросклероза
HK1245122A1 (en) Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US20110319467A1 (en) Absorption Enhancement of Statins and Omega Fatty Acids
FR2951908A1 (fr) Composition comprenant une poudre de nopal et de la levure de riz rouge et complement alimentaire comprenant cette composition
BG66783B1 (bg) Средство за профилактика и регулиране на нивото на общия холестерол
WO2013138411A1 (fr) Substances permettant d'atténuer la survenue d'événements cardiaques majeurs comprenant des acides gras polyinsaturés oméga -3 ou des dérivés correspondants et un extrait de riz à levure rouge à haute teneur en monacoline k
McCosker ATORVASTATIN vs FISH OIL
Sterols Emerging New Ingredients for Cardiovascular Health

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140822